All articles tagged with #glp 1s
As GLP-1 weight‑loss medications become more common, families are navigating how to discuss the drugs with children. Experts advise neutral, non‑weight‑focused language, modeling intuitive eating, and letting kids drive the conversation to avoid reinforcing dieting culture, while acknowledging that these meds can change eating habits and body size.
GLP-1 medications used for weight loss can reduce persistent 'food noise'—thoughts about eating and body image—but experts warn that silencing these cues can mask hunger signals and nutritional needs, especially for people with or recovering from eating disorders. While some studies link GLP-1 use to fewer intrusive food thoughts, more research is needed, and clinicians stress monitoring weight, labs, intake, mood, and menstrual health while tailoring treatment to individual needs.
GLP-1 weight-loss drugs like Ozempic are turning casual office chatter into delicate HR and policy debates, as coworkers question body changes, while employers grapple with potential premium impacts and the ethics of sharing medical information. Even though individuals can discuss their own treatment, the conversations raise concerns about privacy, stigma, and fairness, leaving benefits teams balancing empathy with economics in a murky, evolving workplace landscape.
A small phase II trial with 50 participants found that once-daily oral semaglutide reduced heavy drinking days and alcohol-related harms in adults with moderate to severe alcohol-use disorder, compared with placebo, though craving and average drinks per day did not decline; findings suggest GLP-1s could be a convenient harm-reduction option, but larger trials are needed to confirm efficacy.
A Penn Medicine study of about 12,000 adults with type 2 diabetes newly started on GLP-1 drugs (including Ozempic and tirzepatide) found a small but higher risk of alopecia compared with users of other diabetes meds—about 1.6% developed hair loss over roughly two to three years, with GLP-1 users 37% more likely than SGLT-2 inhibitors and 68% more likely than DPP-4 inhibitors. The effect is mainly non-scarring and may be reversible; weight loss and possible nutrient deficiencies (iron, zinc) could drive a telogen effluvium mechanism. The study is observational and cannot prove causation; FDA labeling already lists alopecia as a potential adverse reaction, and ongoing dermatologic surveillance is advised.
A UT Southwestern study of 204,148 youths aged 13–25 treated for obesity found GLP-1 medications (like semaglutide) are increasingly used, with exclusive GLP-1 use rising from 88.2% in 2022 to 96.1% in 2025–2026 and bariatric surgery dropping from 11.6% to 3.7%, signaling a rapid shift in obesity care toward medications for young people, though long‑term effects and treatment sequencing remain uncertain and these drugs should augment—not replace—comprehensive care.
Doctors report three cases of anhedonia (loss of pleasure) in people taking the obese‑treating GLP-1 drug tirzepatide at very high doses (up to 15 mg/week). In all cases, symptoms eased after reducing the dose (and in one case adding an antidepressant), suggesting the effect is dose-related and manageable. The side effect is linked to GLP-1s’ influence on brain reward regions like the ventral tegmental area, though GLP-1 therapies remain associated with reduced depression symptoms overall. Clinicians emphasize monitoring motivation and pleasure during treatment, especially at higher doses, and note that this should not deter indicated use for obesity or type 2 diabetes while remaining vigilant and adjusting dosing as needed.
A new body-contouring injectable called alloClae uses cadaver fat to restore volume in breasts, buttocks, and face, riding a surge in GLP-1 weight-loss users; it’s marketed as off-the-shelf fat grafting and can be injected in under an hour, but faces regulatory pushback (notably New York license denials) and ethical scrutiny over donor consent, with reports of complications like fat necrosis as demand grows and clinics scale up.
Pharma firms are racing to bring pill-form GLP-1 weight-loss drugs to market, with aleniglipron and elecoglipron delivering about 11–12% weight loss over 36 weeks in Phase II, thanks to absorption-enhancers or small-molecule designs, while other candidates like Roche CT-996, Ascletis ASC30, and Viking VK2735 are in development. Even if approved, competition could lower prices and expand options beyond injections like Ozempic/Wegovy.
A large retrospective study across 170 centers found that people with type 2 diabetes using GLP-1 drugs (such as semaglutide found in Ozempic/Wegovy) were about 48% more likely to be diagnosed with smell or taste disturbances than non-users, though the absolute risk is tiny (0.37% vs 0.22%). The findings do not prove causation and call for more research, but clinicians and patients should monitor for anosmia, parosmia, and parageusia, as these could affect diet and quality of life; potential mechanisms may involve GLP-1 receptors in the brain and olfactory system, and early detection could enable interventions like olfactory training.
A University of Louisville–led study published in JAMA Psychiatry finds that among people with eating disorders, about 32% have used GLP-1 medications (e.g., semaglutide in Ozempic/Wegovy) at some point, and roughly 22% are current users—rates much higher than the general public—while about 10% report misuse (such as higher or non-prescribed dosages or sharing). GLP-1s are not indicated for eating disorders, and some individuals may be using them to achieve rapid weight loss or extreme restriction. The researchers emphasize the need for stricter pharmacovigilance as GLP-1 products broaden in form and market reach.
Using All of Us data, researchers analyzed 753 obesity patients prescribed GLP-1 medications (including semaglutide/Ozempic and tirzepatide) who had Fitbit data before/after starting therapy. After initiation, average daily steps fell from 5,047 to 4,487 and moderate-to-vigorous activity dropped from 28 minutes to 22 minutes, suggesting exercise promotion should accompany pharmacologic treatment. The findings are preliminary (to be presented at ENDO 2026) and older adults or those with musculoskeletal pain may be at higher risk for muscle loss.
A Danish Lancet trial found the GLP-1 drug semaglutide reduced alcohol consumption and heavy drinking days over 26 weeks, adding to a growing body of research that GLP-1s may curb cravings for various substances. However, these drugs are not approved for alcohol use disorder and are prescribed today for diabetes or obesity; ongoing studies in the U.S. and elsewhere are exploring effects on other addictions and whether benefits persist after stopping treatment. If future trials confirm efficacy and safety, GLP-1s could become a treatment option pending regulatory approval.
New EPIC Research trackers using COSMOS data show GLP-1 prescriptions have risen fourfold since 2021, while obesity within the dataset declined from 42% to 41%, with GLP-1 users seeing a bigger drop (75% to 69%). While not nationally representative, the trend aligns with CDC estimates and other surveys that show rising GLP-1 use. Barriers like side effects, cost, and insurance limit adoption (about 12% of Americans), and cheaper generics abroad could arrive in five years. If adoption continues, obesity could decline further, though long-term effects remain uncertain.
A Glamour-style piece documents how GLP-1 drugs once reserved for medical weight management are being used off-label for cosmetic goals, including compounded versions and microdosing via telehealth. It weaves patient anecdotes with medical perspectives, highlights risks like side effects and gut–microbiome effects, and shows a growing push-pull between health benefits and the influencer-driven hype. The author begins a low-dose Zepbound plan under a doctor’s supervision and reports initial weight loss, while stressing the need for cautious, evidence-based use as these drugs become more accessible.